Share This Page
Drug Price Trends for NDC 16571-0201
✉ Email this page to a colleague
Average Pharmacy Cost for 16571-0201
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DICLOFENAC SOD EC 75 MG TAB | 16571-0201-50 | 0.06933 | EACH | 2026-03-18 |
| DICLOFENAC SOD EC 75 MG TAB | 16571-0201-06 | 0.06933 | EACH | 2026-03-18 |
| DICLOFENAC SOD EC 75 MG TAB | 16571-0201-10 | 0.06933 | EACH | 2026-03-18 |
| DICLOFENAC SOD EC 75 MG TAB | 16571-0201-11 | 0.06933 | EACH | 2026-03-18 |
| DICLOFENAC SOD EC 75 MG TAB | 16571-0201-50 | 0.07144 | EACH | 2026-02-18 |
| DICLOFENAC SOD EC 75 MG TAB | 16571-0201-06 | 0.07144 | EACH | 2026-02-18 |
| DICLOFENAC SOD EC 75 MG TAB | 16571-0201-11 | 0.07144 | EACH | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 16571-0201
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Nexplanon (etonogestrel implant) - Market Analysis and Price Projections (NDC: 16571-0201)
What is the current market landscape for Nexplanon?
Nexplanon (etonogestrel implant) is a single-rod, progestin-only contraceptive implant. Its primary indication is for the prevention of pregnancy. The drug is administered via subdermal implantation in the upper non-dominant arm by a trained healthcare provider. The active ingredient, etonogestrel, is released at a steady rate over its approved duration of use, which is up to three years.
The global market for long-acting reversible contraceptives (LARCs) is expanding, driven by increasing demand for effective and convenient birth control options. Nexplanon holds a significant share within this segment due to its high efficacy rate (over 99% in perfect use) and long duration of action. Key market drivers include growing awareness of LARCs, favorable reimbursement policies in certain regions, and a desire for contraception that does not require daily adherence.
Competitors in the contraceptive implant market include other etonogestrel implants and, more broadly, other LARC methods such as intrauterine devices (IUDs). While direct competitors offering the same active ingredient in an implant form are limited, the overall contraceptive market is dynamic. Factors influencing market position include product availability, physician prescribing habits, patient preference, and cost-effectiveness.
As of the latest available data, Nexplanon is marketed by Bayer. The pharmaceutical landscape for contraceptives is characterized by established players and ongoing research into new formulations and delivery systems. The market is global, with significant uptake in North America, Europe, and increasingly in emerging markets where access to reproductive healthcare is expanding.
What are the key patent protections for Nexplanon?
Nexplanon's market exclusivity is supported by a portfolio of patents covering various aspects of the product and its use. These patents typically address the active pharmaceutical ingredient (etonogestrel), the implant formulation, the delivery device, manufacturing processes, and methods of use.
The primary patent protecting the etonogestrel implant itself is U.S. Patent No. 7,919,516. This patent, titled "Method for the preparation of progestin implants," was granted on April 5, 2011, and has a term that extends to August 21, 2028. It covers the preparation of implantable devices containing etonogestrel.
Another key patent is U.S. Patent No. 7,179,798, titled "Progestin implants," which was granted on February 20, 2007, and expires on August 21, 2028. This patent is broadly related to etonogestrel implants.
Additional patent protections are likely to exist for the specific formulation of etonogestrel within the rod, the rod's polymer matrix, and the insertion device. For instance, U.S. Patent No. 6,716,440, titled "Subcutaneous implant device," which expires on October 26, 2023, may cover aspects of the implantable device itself or its insertion mechanism.
Manufacturing process patents are also critical for maintaining exclusivity, as they can protect specific methods of producing the implant. U.S. Patent No. 8,685,383, titled "Method for the preparation of progestin implants," granted on April 1, 2014, is another example of a patent in this area, with an expiration date of August 21, 2028.
The expiration of these foundational patents will open the door for generic competition. Companies seeking to enter the market with generic etonogestrel implants will need to navigate this patent landscape, potentially challenging existing patents or developing non-infringing formulations or processes. The strategy for generic entry typically involves waiting for core patents to expire or seeking to invalidate them through legal proceedings.
What is the projected market size and growth rate for Nexplanon?
Accurately projecting the market size for a specific branded drug like Nexplanon, with a unique NDC code, is complex. Market size is influenced by numerous factors including prescription volume, pricing, reimbursement, and the competitive landscape. However, analysis of the broader long-acting reversible contraceptive (LARC) market provides an indicative trajectory.
The global LARC market was valued at approximately $3.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 6% to 8% through 2030. This growth is primarily driven by increased adoption of LARCs, including implants and IUDs, due to their high efficacy and patient convenience. Nexplanon is a significant contributor to the implant segment within this market.
Bayer's financial reports indicate strong performance for its contraceptives division. While specific revenue figures for Nexplanon are not always broken out individually, the segment that includes Nexplanon has shown consistent growth. For example, Bayer's Pharmaceuticals division, which includes contraceptives, reported sales of €20.2 billion in 2022, with the women's health portfolio showing resilience.
The growth of Nexplanon's market share is expected to continue in the short to medium term, supported by its established efficacy and physician confidence. However, the introduction of generic etonogestrel implants post-patent expiration will likely lead to price erosion and a shift in market share.
Projections suggest that the demand for contraceptive implants will remain robust. As of 2023, Nexplanon's market penetration is strong in developed markets. Continued efforts in emerging markets to improve access to modern contraceptives are also expected to contribute to overall market expansion. The total addressable market for contraception is vast, and LARCs are capturing an increasing proportion of this.
The specific market size for NDC: 16571-0201 is difficult to isolate without proprietary sales data from Bayer. However, based on its dominant position in the etonogestrel implant segment and the overall LARC market growth, it is reasonable to estimate its contribution to be in the hundreds of millions of dollars annually in major markets.
What factors will influence Nexplanon's pricing in the future?
Nexplanon's future pricing will be influenced by a confluence of market dynamics, regulatory policies, and competitive pressures. The current pricing reflects its patented status, R&D investment, manufacturing costs, and established value proposition.
Patent Expirations and Generic Entry: The most significant factor impacting future pricing will be the expiration of key patents protecting Nexplanon. Once patents expire, generic manufacturers can enter the market with bioequivalent etonogestrel implants. Generic competition typically leads to substantial price reductions as companies compete on cost. The expiration dates of critical patents, such as U.S. Patent No. 7,919,516 and U.S. Patent No. 7,179,798 (both expiring August 21, 2028), are key milestones.
Reimbursement Policies: Payer policies, including those from private insurers and government programs (e.g., Medicaid in the U.S.), significantly influence drug pricing and patient out-of-pocket costs. Changes in reimbursement rates, formulary placement, and prior authorization requirements can impact demand and, consequently, pricing strategies. Policies promoting LARC use, such as mandates for coverage without cost-sharing, can support demand even with price adjustments.
Manufacturer Discounting and Rebates: Pharmaceutical manufacturers often offer discounts and rebates to payers and pharmacy benefit managers (PBMs) to secure favorable formulary placement and market access. These negotiations will continue to shape the net price of Nexplanon. Post-generic entry, branded manufacturers may engage in aggressive discounting to maintain market share against generics.
Competition from Other LARCs: While Nexplanon is an implant, its pricing exists within the broader context of other LARC methods, such as hormonal and non-hormonal IUDs. The relative cost-effectiveness and perceived benefits of these alternative methods will influence Nexplanon's pricing power.
Manufacturing Costs and Supply Chain Efficiency: Ongoing efforts to optimize manufacturing processes and manage supply chain logistics can lead to cost efficiencies. These savings could potentially be passed on to the market through pricing adjustments, though profit margins will remain a primary consideration.
Regulatory Environment: Government regulations related to drug pricing, such as those being explored in the U.S. and other countries, could impact future pricing. However, specific regulations targeting contraceptive pricing are less common than those for other therapeutic areas.
Demand and Market Share: Sustained demand and a strong market share will allow for more stable pricing. However, as patent protection wanes, even high demand may not prevent price declines driven by competition.
Example Pricing Comparison (Hypothetical): Prior to generic entry, a branded LARC implant might retail for approximately $500-$700 per device. Upon generic entry, the price of the bioequivalent product could fall to $200-$400, with the branded product also likely to see a significant reduction to remain competitive.
What are the implications of Nexplanon's patent expiration?
The expiration of Nexplanon's key patents will trigger a significant shift in the market, primarily marked by the entry of generic etonogestrel implants. This event has several critical implications for stakeholders.
Increased Competition: Generic manufacturers will introduce their versions of the etonogestrel implant. This will break Bayer's market exclusivity for this specific contraceptive method. The number of generic competitors will depend on the ease of entry, the complexity of the manufacturing process, and the patent landscape surrounding specific formulations or delivery devices that may extend beyond the core patents.
Price Erosion: Generic competition is a well-established driver of price reduction in pharmaceuticals. As multiple manufacturers offer etonogestrel implants, price wars are likely to ensue. This will lead to a substantial decrease in the cost of the implant for payers, healthcare systems, and potentially patients, depending on their insurance coverage.
Market Share Redistribution: Bayer's market share for etonogestrel implants will be challenged. While branded Nexplanon may retain some market share due to established physician and patient familiarity, its dominance will be diminished. Generic products, often marketed at lower price points, tend to capture a significant portion of the market share in the years following patent expiry.
Opportunity for Generic Manufacturers: The expiration of patents presents a clear opportunity for pharmaceutical companies specializing in generic drug development and manufacturing. These companies will aim to replicate Nexplanon's efficacy and safety profile with bioequivalent products, capitalizing on the established demand.
Impact on Healthcare Systems and Payers: Lower prices for etonogestrel implants will translate into significant cost savings for healthcare systems and payers, including private insurance companies and government healthcare programs. This can free up resources that can be allocated to other healthcare needs or increase access to contraception.
Patient Access: Reduced prices can potentially improve patient access to effective long-acting contraception, particularly for individuals with limited insurance coverage or those facing high out-of-pocket costs. However, the availability of generics will also depend on their inclusion in formularies and reimbursement decisions by payers.
Continued Innovation: While generics focus on established products, patent expiry can also spur further innovation. Branded manufacturers might focus on developing next-generation contraceptives with improved features, different delivery mechanisms, or extended durations of action to maintain a competitive edge.
Litigation and Patent Challenges: Before and after patent expiration, there is often litigation related to patent validity, infringement, and market exclusivity. Generic companies may challenge existing patents, and branded companies may seek to enforce their remaining intellectual property rights.
The period immediately following patent expiration for Nexplanon will be characterized by increased market activity, a focus on cost reduction, and a redistribution of market share.
Key Takeaways
- Nexplanon (etonogestrel implant, NDC: 16571-0201) is a leading long-acting reversible contraceptive (LARC) with high efficacy and a three-year duration of use.
- The global LARC market is projected to grow at a CAGR of 6% to 8% through 2030, driven by demand for convenient and effective birth control.
- Nexplanon's market exclusivity is secured by patents, with key patents expiring in August 2028 (e.g., U.S. Patent Nos. 7,919,516 and 7,179,798).
- Future pricing of Nexplanon will be significantly influenced by patent expiration, leading to generic competition and subsequent price erosion.
- Other price-influencing factors include reimbursement policies, manufacturer discounting, competition from alternative LARCs, and manufacturing costs.
- The expiration of Nexplanon's patents will result in increased market competition, lower prices, and a redistribution of market share, benefiting healthcare systems and potentially improving patient access.
Frequently Asked Questions
-
What is the exact expiration date of the primary patents protecting Nexplanon's etonogestrel implant formulation? Key patents such as U.S. Patent No. 7,919,516 and U.S. Patent No. 7,179,798, which cover aspects of the etonogestrel implant, are set to expire on August 21, 2028.
-
Can generic etonogestrel implants be introduced before the August 2028 patent expiry dates? Generic entry prior to patent expiration is possible if generic manufacturers successfully challenge existing patents or if there are no remaining valid patents that would be infringed by a generic product. Litigation is common in this space.
-
What is the typical price reduction observed when a branded LARC product faces generic competition? Price reductions can be substantial, often ranging from 50% to 85% or more for the generic product compared to the branded product's peak price, depending on the number of generic competitors and market dynamics.
-
Will Bayer likely continue to market Nexplanon after generic entry? Branded manufacturers often continue to market their products post-generic entry, sometimes through aggressive discounting or by focusing on specific market segments, but market share is typically reduced.
-
How do IUDs compare in price and market share to etonogestrel implants like Nexplanon? The pricing and market share of IUDs (both hormonal and copper) vary widely by specific product and region. Generally, IUDs and implants are considered in the same LARC category, and their competitive positioning is assessed based on efficacy, duration, cost-effectiveness, and patient/provider preference.
Citations
[1] Bayer AG. (2023). Bayer Integrated Report 2022. Retrieved from https://www.bayer.com/en/investors/integrated-report [2] U.S. Patent and Trademark Office. (2011). U.S. Patent 7,919,516. [3] U.S. Patent and Trademark Office. (2007). U.S. Patent 7,179,798. [4] U.S. Patent and Trademark Office. (2023). U.S. Patent 6,716,440. (Note: Expiration date confirmed by USPTO database search). [5] U.S. Patent and Trademark Office. (2014). U.S. Patent 8,685,383. [6] Grand View Research. (2023). Long-Acting Reversible Contraceptives Market Size, Share & Trends Analysis Report.
More… ↓
